Serum Level of Interleukin 6 as a Prognosis Factor in Metastatic Renal Cell Carcinoma

Cancer Research

Volumn 52, Issue 12, 1992, Pages 3317-3322

  May, Jean Yves ^a,b   Negrier, Sylvie ^a   Combaret, Valerie ^a   Attali, Stephane ^a   Goillot, Evelyne ^a   Mercatello, Alain ^b   Ravault, Alain ^c   Tourani, Jean Marc ^b   Moskovtchenko, Jean Francois ^d   Philip, Thierry ^a   Favrot, Marie ^a  

^a CENTRE LÉON BÉRARD   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c INSTITUT BERGONIÉ   (France)

^d Hopital Laennec   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; INTERLEUKIN 2; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HIGH RISK POPULATION; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; FEMALE; HUMAN; INTERLEUKIN-2; INTERLEUKIN-6; KIDNEY NEOPLASMS; MALE; MIDDLE AGE; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS;

EID: 0026625812     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Linehan, W. M., Shipley, W. U., and Longo, D. Cancer of the kidney and ureter. In: V. De Vita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer Principles and Practice of Oncology, pp 979-1007 Philadelphia: J. B. Lippincott, 1989.
2. Selli, C., Hinshaw, W. M., Woodard, B. H., and Paulson, D. F. Stratification of risk factors in renal cell carcinoma. Cancer (Phila.), 52:899-903, 1983.
3. Maldazys, J. D., and deKemion, J. B. Prognostic factors in metastatic renal carcinoma. J. Urol., 136:376-379, 1986.
4. De Forges, A., Rey, A., Klink, M., et al. Prognostic factors of adult metasutic renal carcinoma: a multivariate analysis. Semin. Surg. Oncol., 4: 149-154, 1988.
5. Elson, P. J., Witte, R. S., and Trump, D. L. Prognostic factors for survival in patients with recurrent or metastatic renal carcinoma. Cancer Res., 48: 7310-7313, 1988.
6. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. T., Skibber, J. M., Shiloni, E., Vetto, J. T., Seipp, C. A., Simpson, C., and Reichert, C. M. Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant IL-2 to patients with metastatic cancer. N. Engl. J. Med., 313: 1485-1492, 1985.
7. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Leitman, S., Avis, F. P., Linehan, W. M., Robertson, G. M., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C., and White, D. E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med., 316:889-897, 1987.
8. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S., and White, D. E. Combination therapy with interleukin 2 and alpha interferon for the treatment of patients with advanced cancer. J. Clin. Oncol., 7: 1863-1874,1989.
9. West, W. H., Taner, K. W., Yanelli, J. R., Marshall, G. D., Orr, D. W., Thurmann, G. B., and Oldham, R. T. Constant infusion recombinant IL-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med., 316:898-905, 1987.
10. Fischer, R. I., Coltman, C. A., Doroshow, J. H., Rayner, A. A., Hawkins, M. J., Mier, J. W., Wiemick, P., Mac Dannis, J. D., Weiss, G. R., Margolin, K. A., Gemlo, B. T., Hoth, D. F., Parkinson, D. R., and Paietta, E. Metastatic renal cell cancer treated with IL-2 and lymphokine activated killer cells. A phase II Trial. Ann. Intern. Med., 108:518-523, 1988.
11. Philip, T., Mercatello, A., Negrier, S., Philip, I., Rebattu, P., Kammerlen, P., Gaspard, M., Tognier, E., Combaret, V., Bijman, B. T., Franks, C. R., Chauvin, F., Moskovtchenko, J. F., Favrot, M. C., and Clavel, M. Interleukin 2 with or without LAK cells in metastatic renal cell carcinoma: the Lyon first year experience on 20 patients. Cancer Treat. Rev. 16 (Suppl. A); 91-104, 1989.
12. Negrier, S., Philip, T., Stoter, G., Fossa, S. D., Janssen, S., lacono. A., Cleton, F. S., Israel, L., Jasmin, C., Rugarli, C., Masse, H. V. D., Thatcher, N., Symann, M., Bartsch, H. H., Bergmann, L., Bijman, J. T., Palmer, P. A., and Franks, C. R. Interleukin 2 with or without LAK cells in metastatic renal carcinoma: a report of a European Multicenter study. Eur. J. Cancer Clin. Oncol., 25: S21-S28,1989.
13. Atzpodien, J., Korfer, A., Franks, C. R., Poliwoda, H., and Kirchner, H. Home therapy with recombinant IL-2 and recombinant interferon alpha 2b in advanced human malignancies. Lancet, 335:1509-1512, 1990.
14. Fischer, B., Keenan, A. M., Garra, B. S., Steinberg, S., White, D. E., Dibisceglie, A. M., Hoofnagle, G. H., Yolles, P., Rosenberg, S. A., and Lotze, M. T. Interleukin 2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J. Clin. Oncol., 7: 1852-1862,1989.
15. Lee, R. E., Lotze, M. T., Skibber, J. M., Tucker, E., Bonow, R. O., Ognibene, F. P., Carrasquilo, G. A., Sheldaner, J. H., Parillo, J. E., and Rosenberg, S. A. Cardiorespiratory effects of immunotherapy with IL-2. J. Clin. Oncol., 7: 7-20,1989.
16. Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S., Nakajima, S., Koyama, K., Iwamatsu, A., Tsusanawa, S., Sakiyama, F., Matsui, H., Takahara, Y., Taniguchi, T., and Kishimoto, T. Complementary DNA for a novel interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (Lond.), 324:73-79,1986.
17. Kishimoto, T. The Biology of interleukin 6. Blood, 74: 1-10,1990.
18. Hirano, T., Akira, S., Taga, T., and Kishimoto, T. Biological and clinical aspects of interleukin 6. Immunol. Today, II: 443-449, 1990.
19. Zilberstein, A., Ruggieri, R., Korn, J. H., and Revel, M. Structure and expression of cDNA and genes for human interferon 92, a distinct species inducible by growth-stimulatory cytokines. EMBO J., 5:2529-2535,1986.
20. Haegeman, G., Content, J., Volckaert, G., et al. Structural analysis of the sequence encoding for an inducible 26 kD protein in human fibroblasts. Eur. J. Biochem., 759:625-632,1986.
21. VanDamme, J., Opdenakker, G., Simpson, R. J., Rubira, M. R., Cayphas, S., Vinck, A., Billiau, A., and VanSnick, J. Identification of the human 26 kD protein, interferon ß2, as a B cell hybridoma/plasmocytoma growth factor induced by interleukin 1 and tumor necrosis factor. J. Exp. Med., 165: 914-919, 1987.
22. VanSnick, J. V., Cayphas, S., Szikora, J. P., Szikora, J. P., Renault, J. C., VanRoost, E., Boon, T., and Simpson, R. J. cDNA cloning of murine interleukin HPl: homology with interleukin 6. Eur. J. Immunol., IS: 193-198, 1988.
23. Hirano, T., Taga, T., Yasukawa, K., Nakjyima, K., Nakano, N., Takatsuki, F., Shimizu, M., Maini, R., Feldman, M., and Kishimoto, T. Human B cell differentiation factor defined by an antipeptide antibody and its possible role in autoantibody production. Proc. Natl. Acad. Sci. USA, 84:228-232,1987.
24. Tosato, G., and Pike, S. Interferon ß2/IL-6 is a costimulant for human T lymphocytes. J. Immunol., 141: 1556-1562,1988.
25. Takai, Y., Wong, G. G., Clark, S. C., Burakoff, S. J., and Herrmann, S. H. B cell stimulatory factor 2 is involved in the in vitro induction of cytotoxic T lymphocytes. J. Immunol., 140: 508-514,1988.
26. Kuhweide, R., Van Damme, J., and Ceuppens, J. L. TNF alpha and interleukin 6 synergistically induce T cell growth. Eur. J. ImmunoL, 20:1019-1025, 1990.
27. Houssiau, F., Coulie, P. G., Olive, D., and Van Snick, J. Synergistic activation of human T cells by IL-1 and IL-6. Eur. J. Immunol., 18:653-656,1988.
28. Luger, T. A., Knitmann, J., Kimbauer, R., Urbanski, A., Schwartz, T., Klappacher, G., Kock, A., Micksche, M., Malejczyk, J., Schauer, E., May, L. T., and Sehgal, P. B. IFN/52/IL-6 augments the activity of human natural killer cells. J. Immunol., 143: 1206-1209,1989.
29. Noma, T., Mizuta, T., Rosen, A., Hirano, T., Kishimoto, T., and Honjo, T. Enhancement of the interleukin 2 receptor expression on T cells by multiple B lymphotropic lymphokines. Immunol. Lett., 15:249-254, 1987.
30. Gauldie, J., Richards, C., Hamish, D., Lansdorp, P., and Baumann, H. Interferon beta 2/BSF2 shares identity with monocyte derived hepatocyte stimulating factor and regulates the miuor acute phase protein in liver cells. Proc. Natl. Acad. Sci. USA, 84:7251-7255, 1987.
31. Castell, J. V., Gomez-Lechon, M. J., David, M., Hirano, T., Kishimoto, T., and Heinrich, P. C. Acute phase response of human hepatocytes: regulation of acute phase protein synthesis by IL-6. Hepatology, 12: 1179-1186, 1990.
32. Bataille, R., Jourdan, M., Zhang, X. G., and Klein, B. Serum levels of interleukin 6, a potent myeloma growth factor, as a reflect of disease severity in plasma cell dyscrasias. J. Clin. Invest., 84:2008-2011, 1988.
33. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A., and Kishimoto, T. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma. Nature (Lond.), 322:83-86, 1988.
34. Shimizu, S., Hirano, T., Yoshioka, K., Sugai, S., Matsuda, T., Taga, T., Kishimoto, T., and Konda, S. IL-6 dependent growth of a Lennert's lymphoma-derived T cell line (KT3). Blood, 72: 1826-1830,1988.
35. Biondi, A., Rossi, V., Bassan, R., Iscove, N. N., DeSousa, J., Aarden, L. A., Wong, G. G., Clark, S. C., Messner, H. A., and Minden, M. D. Constitutive expression of the interleukin 6 gene in chronic lymphocytic leukemia. Blood, 73: 1279-1284, 1989.
36. Corbeil, J., Evans, L. A., Vasak, E., Cooper, D. A., and Penny, R. Culture and properties of cells derived from Kaposi sarcoma. J. Immunol., 146: 2972-2976, 1991.
37. Miki, S., Iwano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T., and Kishimoto, T. IL-6 functions as an autocrine growth factor in renal carcinomas. FEBS Lett., 250:607-610,1989.
38. Takenawa, J., Kanako, Y., Fukyumoto, M., Fukatsu, A., Hirano, T., Fukuyama, H., Nakayama, H., Fujita, J., and Yoshida, O. Enhanced expression of IL-6 in primary human renal cell carcinoma. J. Natl. Cancer Inst., 83: 1668-1672,1991.
39. Nijstein, M. W. N., DeGroot, E. R., Ten Duis, J. H., Hack, C. E., and Aarden, L. A. Serum levels of interleukin 6 and acute phase responses. Lancet, 1:291, 1987.
40. Serve, H., Steinhauser, G., Oberberg, B., Flegel, W. A., NorthofT, H., and Berdell, W. E. Studies on the interaction between interleukin 6 and human malignant non hematopoietic cell lines. Cancer Res., 51:3862-3866,1991.
41. Dinarello, C. A. Interleukin 1 and interleukin 1 antagonism. Blood, 77: 1627-1644,1991.
42. Beutler, B., and Cerami, A. Cachectin: a macrophage hormone gov cellular metabolism and cellular response. Endocr. Rev., 9:57-66,1988.
43. Blay, J-Y., Favrot, M. C., Negrier, S., Combaret, V., Chouaib, S., Mercatello, A., Kaemmerlen, P., Franks, C. R., and Philip, T. Correlation between clinical response to IL-2 therapy and sustained production of TNF. Cancer Res., 50: 2371-2374, 1990.
44. Blay, J-Y., Negrier, S., Combaret, V., Merrouche, Y., Mercatello, A., Moskovtchenko, J. F., Philip, T., and Favrot, M. Analyse des modifications des concentrations seriques de TNF, d*IL-l et d*IL-6 au cours de Tadministration d'IL-2. Bull. Cancer, 79:55-65, 1992.
45. Tanner, J., and Tosato, G. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J. Clin. Invest., 88:239-247, 1991.
46. Favrot, M. C., Combaret, V., Negrier, S., Philip, I., Freydel, C., Bijman, J. T., Franks, C. R., Mercatello, A., Kaemmerlen, P., and Philip, T. Functional and immunophenotypic modifications induced by IL-2 did not predict the response to therapy in patients with metastatic renal carcinoma. J. Biol. Response Modif., 9:167-177,1990.
47. Tritarelli, E., Rocca, E., Testa, U., Boccoli, G., Camagna, A., Calabresi, F., and Peschle, C. Adoptive immunotherapy with high dose interleukin 2: kinetics of circulating progenitors correlate with interleukin 6, granulocyte colony stimulating factor level. Blood, 74:741-749,1991.